| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 04/30/2002 | US6380173 Use of low-molecular-weight heparins for the prevention and treatment of trauma of the central nervous system |
| 04/30/2002 | US6380170 Nucleic acid construct for the cell cycle regulated expression of structural genes |
| 04/30/2002 | US6379913 A polypeptide encoding an amino acid sequence; prevention and therapy for diabetes, inflammatory glomerulonephritis, ischemis renal failure, artherosclerosis, coronary vasoconstriction and ischemic heart disease |
| 04/30/2002 | US6379649 Useful for diagnosis and treatment, including radiotherapy, of disorders that are characterized by an abnormal density of peripheral benzodiazepine receptors; nerve system disporders |
| 04/30/2002 | CA2360049A1 Assays for identifying phosphatase inhibitors |
| 04/30/2002 | CA2358678A1 Heterocyclic derivatives useful as pharmaceutical agents |
| 04/30/2002 | CA2233541C 8-azabicyclo[3.2.1]oct-2-ene derivatives, their preparation and use |
| 04/30/2002 | CA2147162C Remyelination using neural stem cells |
| 04/30/2002 | CA2042937C Treatment of ocular hypertension with a synergistic combination |
| 04/30/2002 | CA2042936C Treatment of ocular hypertension with a synergistic combination for ophthalmic use |
| 04/26/2002 | CA2359877A1 Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease |
| 04/25/2002 | WO2002033101A1 Chimeric cytoplasmic signalling molecules derived from cd137 |
| 04/25/2002 | WO2002033100A2 Regulation of human adenylate cyclase, type iv |
| 04/25/2002 | WO2002033099A2 Human kinases |
| 04/25/2002 | WO2002033096A2 Regulation of human serine-threonine protein kinase |
| 04/25/2002 | WO2002033095A2 Regulation of human serine-threonine protein kinase |
| 04/25/2002 | WO2002033080A2 Regulation of human netrin binding membrane receptor unc5h-1 |
| 04/25/2002 | WO2002033079A2 Human g-protein coupled receptor and uses thereof |
| 04/25/2002 | WO2002033049A1 Human tuberoinfundibular peptide of 39 residues |
| 04/25/2002 | WO2002033042A2 Recombinant antibody fragments as autoantibody antagonists |
| 04/25/2002 | WO2002032961A2 Novel polypeptides and nucleic acids encoding same |
| 04/25/2002 | WO2002032958A2 Polynucleotide and polypeptide sequences of human dendritic cell immunoreceptors |
| 04/25/2002 | WO2002032932A2 Urotensin-ii agonists and antagonists |
| 04/25/2002 | WO2002032901A2 Bridged piperazine derivatives |
| 04/25/2002 | WO2002032900A2 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents |
| 04/25/2002 | WO2002032897A1 Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists |
| 04/25/2002 | WO2002032896A1 Furazanyl-triazole derivates for the treatment of diseases |
| 04/25/2002 | WO2002032893A2 Piperidine compounds as anti-allergic |
| 04/25/2002 | WO2002032880A1 New derivatives of cyano-aryl (or cyanoheteroaryl)-carbonyl-piperazinyl-pyrimidines, their preparation and application as medication |
| 04/25/2002 | WO2002032879A1 Dihydropyrimidine derivatives as cysteine protease inhibitors |
| 04/25/2002 | WO2002032867A1 Chemical compounds |
| 04/25/2002 | WO2002032863A1 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy |
| 04/25/2002 | WO2002032858A1 Cycloalkylfluorosulfonamide derivatives |
| 04/25/2002 | WO2002032842A2 Compounds with high monoamine transporter affinity |
| 04/25/2002 | WO2002032507A1 7-amino-2-alkylthiopteridin-4-yl-amines for the treatment of chemokine-related diseases |
| 04/25/2002 | WO2002032449A2 Method for treating ischemic events affecting the central nervous system |
| 04/25/2002 | WO2002032447A2 Cell damage inhibitor |
| 04/25/2002 | WO2002032444A1 Novel medicinal herbal composition for treating liver diseases and hiv |
| 04/25/2002 | WO2002032443A1 Saururus chinensis extract for prevention and treatment of neurodegenerative disease |
| 04/25/2002 | WO2002032434A1 S-adenosylmethionine and derivatives thereof for the treatment and prevention of alzheimer"s disease |
| 04/25/2002 | WO2002032422A2 Ep4 receptor inhibitors to treat rheumatoid arthritis |
| 04/25/2002 | WO2002032417A1 Pharmaceutical preparations containing a dibenzocyclooctane lignan derivative for prevention and treatment of neurodegenerative disease |
| 04/25/2002 | WO2002032412A2 Combination use of acetylcholinesterase inhibitors and gabaa inverse agonists for the treatment of cognitive disorders |
| 04/25/2002 | WO2002032411A2 Combination of statins and sorbitol dehydrogenase inhibitors |
| 04/25/2002 | WO2002032400A1 Liposomal formulation of mitoxantrone |
| 04/25/2002 | WO2002032389A1 Method of treating stroke |
| 04/25/2002 | WO2002032377A2 Estrogen receptor modulators |
| 04/25/2002 | WO2002032373A2 Estrogen receptor modulators |
| 04/25/2002 | WO2002032234A1 Anti-stress composition designed to be mainly incorporated in nutritional carriers |
| 04/25/2002 | WO2002022112A9 Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production |
| 04/25/2002 | WO2002010137A3 Indazole derivatives as JNK inhibitors |
| 04/25/2002 | WO2001089500A3 Agents and methods for increasing brain chaperonin levels |
| 04/25/2002 | WO2001078754A3 Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof |
| 04/25/2002 | WO2001072831A3 Immunoregulator |
| 04/25/2002 | WO2001070208A3 Hormone replacement therapy using a combination of conjugated estrogens and medroxyprogesterone acetate |
| 04/25/2002 | WO2001068880A3 Estrogen-regulated myo-inositol phosphate synthase: compositions and methods of use |
| 04/25/2002 | WO2001058891A3 Piperazine and piperidine derivatives for treatment or prevention of neuronal damage |
| 04/25/2002 | WO2001058450A3 Use of central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation |
| 04/25/2002 | WO2001057240A3 Interaction of nmda receptor with protein tyrosine phosphatase |
| 04/25/2002 | WO2001056990A3 Pyridine derivates as potentiators of glutamate receptors |
| 04/25/2002 | WO2001047533A3 INHIBITION OF GSK-3$g(b) |
| 04/25/2002 | WO2001045687A3 Use of bioactive metabolites of gepirone for the treatment of psychological disorders |
| 04/25/2002 | WO2001043753A3 Combination of ginseng and ginkgo to improve cognitive skills |
| 04/25/2002 | WO2001042471A3 Polypeptides and polynucleotides encoding same |
| 04/25/2002 | WO2001010431A3 Headache and colic relief composition with asafetida and method of use thereof |
| 04/25/2002 | US20020049344 New vitamin d derivatives with carbo-or heterocyclic substituents at c-25, a process for their production, intermediate products and their use for producing medicaments |
| 04/25/2002 | US20020049330 Such as 5-(N,N-dibenzyl)aminocarbonyl-2-pyridone; enzyme inhibitors; for treatment of Alzheimer's disease |
| 04/25/2002 | US20020049329 Novel human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them |
| 04/25/2002 | US20020049301 For therapy of cancer, diabetes, obesity, diseases of the central nervous system, inflammatory disorders, autoimmune dieseases cardiovascular diseases, for generating antibodies |
| 04/25/2002 | US20020049255 Method of treating neurodegenerative disorders of the retina and optic nerve head |
| 04/25/2002 | US20020049251 Wedelolactone and its synthesis for treating neurodegenerative diseases |
| 04/25/2002 | US20020049250 PPAR receptor activator compounds for treating cutaneous disorders/afflictions |
| 04/25/2002 | US20020049243 Pyrrolidine derivatives |
| 04/25/2002 | US20020049241 Conformationally rigid bicyclic and adamantane derivatives useful as alpha2-adrenergic blocking agents |
| 04/25/2002 | US20020049239 Novel indole and benzothiazole derivatives |
| 04/25/2002 | US20020049236 Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases |
| 04/25/2002 | US20020049233 Oral fast-melt dosage form of a cyclooxygenase-2 inhibitor |
| 04/25/2002 | US20020049232 Method of treating parkinson's disease |
| 04/25/2002 | US20020049229 Agents for treating neuropathic pain |
| 04/25/2002 | US20020049226 Treating obesity, hyperlipidemia, glaucoma, arrhythmia, skin disorders, thyroid disease, hypothyroidism, diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, hypercholesteremia, depression and osteoporosis |
| 04/25/2002 | US20020049225 Quinuclidine-substituted aryl compounds for treatment of disease |
| 04/25/2002 | US20020049220 Substituted azoles |
| 04/25/2002 | US20020049218 2-, 6, and 9-substituted purine derivatives, particularly 2(1-R hydroxymethylpropylamino)-6-benzylamino-9-isopropyl purine, used as drug and herbicide; inhibiting effect with respect to cyclin-dependent kinase proteins |
| 04/25/2002 | US20020049214 Aralkyl and aralkylidene heterocyclic lactams and imides as selective agonists and antagonists of serotonin 1 (5-HT1) recepor, used in treating hypertension and all forms of depression |
| 04/25/2002 | US20020049212 Benzimidazole compounds and salts containing piperidine ring are useful in treatment or prevention or medical conditions selected from pain, and inflammatoy diseases; analgesics |
| 04/25/2002 | US20020049211 Combination treatment for depression and anxiety |
| 04/25/2002 | US20020049210 Heteroaryl amines as novel acetylcholinesterase inhibitors |
| 04/25/2002 | US20020049209 Dopamine D4 ligands for the treatment of novelty-seeking disorders |
| 04/25/2002 | US20020049208 Imidazo[1,2-a]pyrazines for the treatment of neurological disorders |
| 04/25/2002 | US20020049207 Nitrogen containing heterobicyclic compounds for treating disorders manifesting hypersecretion of corticotropin releasign factor(CRF) in a warm-blooded animals, such as stroke |
| 04/25/2002 | US20020049206 Compounds for the treatment of addictive disorders |
| 04/25/2002 | US20020049203 CRF receptor antagonists and methods relating thereto |
| 04/25/2002 | US20020049202 Administering halogenated amidino or oxyamidino compound to treat diseases caused by nitric oxide synthase |
| 04/25/2002 | US20020049199 N-linked carbamates and ureas of heterocyclic thioesters |
| 04/25/2002 | US20020049195 Urea compounds that are muscarinic receptor antagonists and agonists, administering to the mammal the urea compound to treat urinary incontinence, chronic pulmonary obstructive disease, asthma, hyper salivation, blurred vision etc. |
| 04/25/2002 | US20020049194 A benzoazepin or benzodiazepin derivatives, shows excellent anti-vasopressin activity, vasopressin agonistic activity and oxytocin antagonistic activity, and are useful as antagonist |
| 04/25/2002 | US20020049193 Inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity. |
| 04/25/2002 | US20020049183 Phospholipids, espeically phosphatidylethanolamines, covalently bound to physiologically acceptable monomers or polymers. |
| 04/25/2002 | US20020049182 Administering to a mammal a composition containing pyrimidine nucleotide precursors in amounts sufficient to treat symptoms resulting from mitochondrial respiratory chain deficiencies. |
| 04/25/2002 | US20020049164 Prodrugs of DP IV-inhibitors |